December 15, 2015

Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data

December 15, 2015 11:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the… Read More
learn more
December 15, 2015

Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data

December 15, 2015 11:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the… Read More
learn more
December 15, 2015

Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone… Read More
learn more
December 15, 2015

Novocure to Hold Webcast to Discuss JAMA Publication of EF-14 Phase 3 Clinical Trial Data

December 15, 2015 11:05 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a webcast today at 5 p.m. EST to discuss the publication of the EF-14 phase 3 clinical trial results in the Journal of the… Read More
learn more
December 15, 2015

Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone… Read More
learn more
December 15, 2015

Journal of the American Medical Association (JAMA) Publishes Pivotal Phase 3 Data for Optune Plus Temozolomide to Treat Newly Diagnosed Glioblastoma

Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone Data show Optune plus standard of care temozolomide extended overall survival and progression-free survival of newly diagnosed glioblastoma patients compared to temozolomide alone… Read More
learn more
December 14, 2015

New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells December 14, 2015 07:00 AM Eastern Standard Time ST. HELIER,… Read More
learn more
December 14, 2015

New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells December 14, 2015 07:00 AM Eastern Standard Time ST. HELIER,… Read More
learn more
December 14, 2015

New Data on Tumor Treating Fields’ Anti-Mitotic Mechanism of Action Published in Scientific Reports

Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells Tumor Treating Fields disrupt mitotic spindle formation leading to irregular chromosome segregation and mitotic catastrophe in cancer cells December 14, 2015 07:00 AM Eastern Standard Time ST. HELIER,… Read More
learn more
December 3, 2015

Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts

Removal of FDA contraindication increases addressable GBM patient population Removal of FDA contraindication increases addressable GBM patient population December 03, 2015 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–A retrospective analysis of Novocure’s (NASDAQ: NVCR)… Read More
learn more